第二次异基因造血干细胞移植后复发的混合表型急性白血病的补救性治疗:1例报告。

IF 2.3 Q2 HEMATOLOGY
Sabrine Mekni, Rimmel Yosra Kanoun, Saloua Ladeb, Dorra Belloumi, Nour Ben Abdeljelil, Tarek Ben Othman
{"title":"第二次异基因造血干细胞移植后复发的混合表型急性白血病的补救性治疗:1例报告。","authors":"Sabrine Mekni, Rimmel Yosra Kanoun, Saloua Ladeb, Dorra Belloumi, Nour Ben Abdeljelil, Tarek Ben Othman","doi":"10.5045/br.2023.2023061","DOIUrl":null,"url":null,"abstract":"TO THE EDITOR: Mixed phenotype acute leukemia (MPAL) is rare, accounting for approximately 1–4% of acute leukemia (AL) cases [1]. Induction therapy for these cases is often based on acute lymphocytic leukemia (ALL) treatment protocols, followed by allogeneic stem cell transplantation (ASCT). However, post-ASCT relapse after ASCT remains the primary cause of treatment failure. The median overall survival (OS) of patients who relapse after ASCT is extremely poor, with a median 3-year survival rate ranging between 9% and 11% [2]. Recent studies have reported better survival rates with a combination of venetoclax (VEN) and hypomethylating agents (HMA). Here, we describe the case of a 36-year-old patient with B/T MPAL who developed medullary relapse after 2 ASCTs and was successfully treated with VEN and azacitidine (VEN-AZA).","PeriodicalId":46224,"journal":{"name":"Blood Research","volume":null,"pages":null},"PeriodicalIF":2.3000,"publicationDate":"2023-06-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/28/08/br-58-2-118.PMC10310488.pdf","citationCount":"0","resultStr":"{\"title\":\"Venetoclax-azacitidine as salvage therapy for relapsed mixed phenotype acute leukemia after a second allogeneic hematopoietic stem cell transplantation: a case report.\",\"authors\":\"Sabrine Mekni, Rimmel Yosra Kanoun, Saloua Ladeb, Dorra Belloumi, Nour Ben Abdeljelil, Tarek Ben Othman\",\"doi\":\"10.5045/br.2023.2023061\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"TO THE EDITOR: Mixed phenotype acute leukemia (MPAL) is rare, accounting for approximately 1–4% of acute leukemia (AL) cases [1]. Induction therapy for these cases is often based on acute lymphocytic leukemia (ALL) treatment protocols, followed by allogeneic stem cell transplantation (ASCT). However, post-ASCT relapse after ASCT remains the primary cause of treatment failure. The median overall survival (OS) of patients who relapse after ASCT is extremely poor, with a median 3-year survival rate ranging between 9% and 11% [2]. Recent studies have reported better survival rates with a combination of venetoclax (VEN) and hypomethylating agents (HMA). Here, we describe the case of a 36-year-old patient with B/T MPAL who developed medullary relapse after 2 ASCTs and was successfully treated with VEN and azacitidine (VEN-AZA).\",\"PeriodicalId\":46224,\"journal\":{\"name\":\"Blood Research\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":2.3000,\"publicationDate\":\"2023-06-30\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/28/08/br-58-2-118.PMC10310488.pdf\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Blood Research\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.5045/br.2023.2023061\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q2\",\"JCRName\":\"HEMATOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Blood Research","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.5045/br.2023.2023061","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"HEMATOLOGY","Score":null,"Total":0}
引用次数: 0

摘要

本文章由计算机程序翻译,如有差异,请以英文原文为准。

Venetoclax-azacitidine as salvage therapy for relapsed mixed phenotype acute leukemia after a second allogeneic hematopoietic stem cell transplantation: a case report.

Venetoclax-azacitidine as salvage therapy for relapsed mixed phenotype acute leukemia after a second allogeneic hematopoietic stem cell transplantation: a case report.
TO THE EDITOR: Mixed phenotype acute leukemia (MPAL) is rare, accounting for approximately 1–4% of acute leukemia (AL) cases [1]. Induction therapy for these cases is often based on acute lymphocytic leukemia (ALL) treatment protocols, followed by allogeneic stem cell transplantation (ASCT). However, post-ASCT relapse after ASCT remains the primary cause of treatment failure. The median overall survival (OS) of patients who relapse after ASCT is extremely poor, with a median 3-year survival rate ranging between 9% and 11% [2]. Recent studies have reported better survival rates with a combination of venetoclax (VEN) and hypomethylating agents (HMA). Here, we describe the case of a 36-year-old patient with B/T MPAL who developed medullary relapse after 2 ASCTs and was successfully treated with VEN and azacitidine (VEN-AZA).
求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
Blood Research
Blood Research HEMATOLOGY-
CiteScore
3.70
自引率
0.00%
发文量
64
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信